EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSNFUG00015012495
Gene Symbol: GRIK2
3 Cross references
253 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSNFUG00015000764
Gene Symbol: GRIK2
3 Cross references
241 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSNFUG00015000661
Gene Symbol: GRIK3
1 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSNFUG00015002902
Gene Symbol: GRIK5
3 Cross references
232 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSNFUG00015015265
Gene Symbol: GRIK5
1 Cross references
229 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSNFUG00015011848
Gene Symbol: GRM4
3 Cross references
207 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSNFUG00015005026
Gene Symbol: GRM4
3 Cross references
196 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2c-Like

Ensembl ID : ENSNFUG00015000576
Gene Symbol: LOC107378608
3 Cross references
115 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSNFUG00015015789
Gene Symbol: LOC107379570
2 Cross references
212 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSNFUG00015020431
Gene Symbol: LOC107394391
2 Cross references
214 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 3a-Like

Ensembl ID : ENSNFUG00015020647
Gene Symbol: LOC107396711
3 Cross references
245 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 3b-Like

Ensembl ID : ENSNFUG00015025020
Gene Symbol: LOC107392080
3 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).